Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization. by Lilleyman, J. S. et al.
Br. J. Cancer (1984), 49, 703-707
Childhood lymphoblastic leukaemia: Sex difference in
6-mercaptopurine utilization
J.S. Lilleyman1, L. Lennard,2 C.A. Rees', G. Morgan' & J.L. Maddocks2
'Department ofHaematology, The Children's Hospital, Western Bank, Sheffield S10 2TH, and 2University
Department of Therapeutics, The Royal Hallamshire Hospital, Sheffield S10 2JF, UK.
Summary Twelve boys and 10 girls on similar long term remission maintenance treatment for lymphoblastic
leukaemia had 79 random assays of their red cell 6 thioguanine nucleotide (6TGN) concentrations performed
as an index ofcytotoxic activity generated by oral 6-mercaptopurine (6MP).
Correlation between the dose of 6MP and 6TGN was statistically significant in the girls (r=0.58, P<0.001)
but not in the boys (r=0.15). Additionally, as a group the boys tolerated more 6MP (P<0.05), despite
similar prescribing criteria, but this did not result in a higher mean 6TGN concentration or increased
myelotoxicity.
It appears that girls develop 6MP cytotoxicity at lower doses and more predictably than boys. If so, this
may be relevant to the as yet unexplained but marked sex difference in prognosis apparent in some studies.
The cytotoxic effect of 6-mercaptopurine (6MP) can
be related to incorporation of 6MP derived 6-
thioguanine nucleotide (6TGN) into DNA (Tidd &
Paterson, 1974). We have been measuring the
6TGN found in red cells from children taking 6MP
as part of remission maintenance treatment for
acute lymphoblastic leukaemia (ALL), and
somewhat to our surprise, have found a sex
difference in the relationship between 6MP dose,
6TGN concentration and myelosuppression. This
may be relevant to the higher late relapse rate
frequently seen in boys and explain why such a sex
difference in prognosis is found with some
treatment schedules but not others.
Patients and methods
Consecutive children with ALL treated at the
Sheffield Children's Hospital were studied. The
children had all been in complete remission for at
least 6 months, and were treated with an identical
maintenance schedule (the Medical Research
Council regimen UKALL VIII). This consisted of
daily 6MP (75 mg m 2) and weekly methotrexate
(20mg m-2), both oral, and both prescribed as a
target dose based on body surface area. Doses were
reduced to 75%, 50% and 0% of the target on the
basis of neutropenia or thrombocytopenia at the
time of prescription and always in parallel. Both of
these drugs were taken as a single early morning
dose on an empty stomach. Monthly pulses of a
single dose of i.v. vincristine (1.5mgm 2) and 5
days oral prednisone (40mgm-2) were also given to
all patients irrespective of blood counts.
Blood for 6TGN assay was obtained at the time
of venepuncture for vincristine administration, and
so monthly in most children for the study period.
The children had been taking 6MP for between 7
months and 2 years, and were in good health at the
time of assay. As co-trimoxazole has been found to
interfere with 6MP metabolism, (Rees et al., 1984)
it was ensured that no patients were taking this
drug at the time of study, though all received it for
the first 6 months of remission maintenance
treatment as per protocol.
Red blood cell (RBC) 6TGN was assayed by the
method of Lennard & Maddocks (1983). Briefly,
this involved extracting the nucleotide from 100pl
of packed RBCs (containing
- 8 x108 cells) by a
modification of the 6-thioinosinic acid assay of
Fletcher and Maddocks (1980). This was then
hydrolysed to the parent purine, 6-thiogianine,
which was assayed fluorimetrically. The absolute
neutrophil count (ANC) 14 days after sampling for
6TGN assay was used as an index of myelo-
suppression. This time had been found to be
appropriate after a variety of time intervals had
been explored in an earlier study seeking
correlation between 6MP and myelosuppression
(Herber et al., 1982). Statistical analysis was by
Pearson's product-moment correlation coefficient
and Student's t-test.
Results
Twenty-two children with ALL, 12 boys and 10
girls, aged 3-13 years were studied over a period of
11 months. Seventy-nine 6TGN assays were
performed (i.e. - 3 per child) during that time.
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The relationship between 6TGN concentration
and the dose of 6MP, both as a total for the
preceding month and as a daily dose at the time of
assay, are shown for the two sexes in Table I and
Figures 1 and 2. While there was a strong
Table I The relationships between 6-mercaptopurine
(6MP), 6-thioguanine nucleotide (6TGN) and absolute
neutrophil count (ANC) in 22 children (10 girls, 12 boys)
with lymphoblastic leukaemia. The dose of 6MP is
presented as the total dose for the month preceding and
the daily dose at the time of assay for 6TGN. The ANC
was measured two weeks after 6TGN assay.
Correlation Group n r t P
Monthly 6MP dose Girls 40 0.58 4.3 <0.001
vs Boys 39 0.15 0.89 NS
6TGN concentration Total 79 0.34 3.18 <0.01
Daily 6MP dose Girls 40 0.5 3.58 <0.001
vs Boys 39 0.25 1.57 NS
6TGN concentration Total 79 0.37 3.5 <0.001
6TGN concentration Girls 40 -0.46 3.24 <0.01
vs Boys 39 -0.36 2.32 <0.05
ANC two weeks later Total 79 -0.4 3.85 <0.001
Daily 6MP dose Girls 40 -0.47 3.3 <0.01
vs Boys 39 -0.29 1.84 NS
ANC two weeks later Total 79 -0.37 3.47 <0.001
Monthly 6MP dose Girls 40 -0.56 4.16 <0.001
vs Boys 39 -0.3 1.88 NS
ANC two weeks later Total 79 -0.4 3.8 <0.001
NS=not significant.
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correlation in girls, there was no significant
relationship demonstrable in boys.
The relationship between 6TGN concentration
and subsequent neutropenia also showed a
difference between the sexes, but here the difference
was much less marked, and greater numbers may
make it disappear. An attempt to correlate dose
with neutropenia, however, reintroduced a
strikingly significant sex difference as shown in
Table I and Figures 3 and 4.
Table II shows the mean values of the
parameters under consideration from which it is
clear that there is no sex difference between the
TGN and ANC values but that the boys took, as a
group, much higher doses of 6MP despite similar
prescribing criteria.
All this suggests the conclusion that boys develop
6MP mediated cytotoxicity less easily and less
predictably than girls. There is no indication why
this should be so.
Discussion
Given currently available treatment the prognosis
of childhood ALL is variable but many patients
can look forward to prolonged survival and
presumed cure (Pinkel, 1979).
One feature related to prognosis that has
emerged in several recent studies, however, is sex
(George et al., 1979; Medical Research Council
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Figure 1 The relationship between the total 6-mercaptopurine (6MP) dose for the preceding month and 6-
thioguanine nucleotide (6TGN) concentration in the 10 girls studied. Y=9.82 (s.e. 10.41) +0.023 (s.e.
0.0068)x.
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Figure 2 The relationship between the total 6-mercaptopurine (6MP) dose for the preceding month and 6-
thioguanine nucleotide (6TGN) concentration in the 12 boys studied. Y=30.47 (s.e. 16.16)+0.0086 (s.e.
0.0096)x.
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Figure 3 The relationship between the total 6-mercaptopurine (6MP) dose for the month preceding
nucleotide metabolite assay and the absolute neutrophil count (ANC) two weeks after assay in the 10 girls
studied. Y=3.7 (s.e. 0.50)-0.0012 (s.e. 0.0003)x.
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Figure 4 The relationship between the total 6-mercaptopurine (6MP) dose for the month preceding
nucleotide metabolite and the absolute netrophil count (ANC) 2 weeks after the assay in the 12 boys studied.
Y=3.5 (s.e. 071)-0.0008 (s.e. 0.0004)x.
Table II The mean value, standard deviation and range of
6-mercaptopurine (6MP) dose, 6-thioguanine nucleotide (6TGN)
concentration and absolute neutrophil count (ANC) in 22 children
(10 girls, 12 boys) with lymphoblastic leukaemia.
Variable Group n mean range s.d. P
6MP dose, Girls 40 1364 270-2143 562 <0.05
monthly total Boys 39 1617 530-2500 552
(mgm-2) Total 79 1487 572
6TGN Girls 40 251 0-720 180 NS
concentration Boys 39 263 42-958 204
(pmol/8 x 108RBCs) Total 79 257 192
ANC Girls 40 1.95 0.48-6.64 1.49 NS
2 weeks later Boys 39 2.27 0.11-6.9 1.56
(x 1091-1) Total 79 2.11 1.52
NS=not significant.
1978a, 1982). The fact that boys seem to do less
well than girls became apparent about the same
time as generally increasing awareness of the not
uncommon phenomenon of late isolated testicular
disease (Medical Research Council, 1978b) and the
two phenomena became linked in a somewhat
uncritical way, although the incidence of overt and
cryptic testicular infiltration has never explained the
sex difference in response to treatment.
Other explanations have been suggested,
including the difference in X-linked immunity
between the sexes and the natural extension of the
observation that high count T-ALL, a minority
poor prognosis variant of the disease, occurs five
times more frequently in boys (Greaves et al.,
1981). Despite this, however, it must be admitted
that so far no completely satisfactory explanation
has been found. An alternative possibility, that a
sex difference in response to the drugs used might
arise, was suggested by the tentative observation
some time ago that boys apparently tolerated
higher doses of mercaptopurine and methotrexate
during remission maintenance than girls (James &
Mott, 1979). The loss of the sex/prognosis link
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using more aggressive parenteral chemotherapy, as
has now been observed (Heinz et al., 1982) would
also be in accord with this idea.
We were not looking for a sex difference when
we measured RBC 6TGN concentrations in
children on remission maintenance therapy. We did
this simply to assess the relationship with myelo-
suppression and 6MP dose and to explore the use
of the assay as an indirect measurement of
maintenance treatment effectiveness. We were
looking for children whose drug absorption (or
even ingestion) might be impaired. It emerged as a
purely unexpected finding that in our small series of
22 patients the girls showed a significant correlation
between the prescribed dose of 6MP and the RBC
6TGN concentration, whereas the boys did not. We
also confirmed the earlier observation that boys
tolerated higher doses on the same prescribing
criteria. There was little difference in the
relationship between the 6TGN concentration and
subsequent neutropenia, although the correlation in
girls was a little stronger and no significant
difference was apparent in the mean 6TGN concen-
tration and ANC.
These preliminary findings suggest that boys may
develop 6MP mediated cytotoxicity less readily and
less predictably than girls. If true, this is important
because it implies that the problem may be
overcome by monitoring pharmacokinetics more
closely or, as perhaps has already been achieved, by
using more aggressive chemotherapy schedules
which presumably rely less on a delicate balance of
ingestion, absorption and metabolism (Heinz et al.,
1982). If remission maintenance treatment is
relevant in childhood ALL and differing schedules
have certainly produced differing relapse rates
(UKALL V, unpublished), then clearly much more
attention should be paid to what happens to the
prescribed tablets after the children leave the clinic.
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